Literature DB >> 29345008

Current knowledge of risk factors for testicular germ cell tumors.

Tomoya Fukawa1, Hiro-Omi Kanayama1.   

Abstract

The development of the human gonads is tightly regulated by the correct sequential expression of many genes and hormonal activity. Disturbance of this regulation does not only prevent proper development of the gonads, but it also contributes to the development of testicular germ cell tumors. Recent genetic studies, especially genome-wide association studies, have made great progress in understanding genetic susceptibility. Although there is strong evidence of inherited risks, many environmental factors also contribute to the development of testicular germ cell tumors. Histopathological studies have shown that most testicular germ cell tumors arise from germ cell neoplasia in situ, which is thought to be arrested and transformed primordial germ cells. Seminoma has features identical to germ cell neoplasia in situ or primordial germ cells, whereas non-seminoma shows varied differentiation. Seminomas and embryonic cell carcinomas have the feature of pluripotency, which is thought to be the cause of histological heterogeneity and mixed pathology in testicular germ cell tumors. Testicular germ cell tumors show high sensitivity to chemotherapies, but 20-30% of patients show resistance to standard chemotherapy. In the present review, the current knowledge of the epidemiological and genomic factors for the development of testicular germ cell tumors is reviewed, and the mechanisms of resistance to chemotherapies are briefly mentioned.
© 2018 The Japanese Urological Association.

Entities:  

Keywords:  chemotherapy resistance mechanism; epidemiologic risk factor; genomic risk factor; testicular germ cell tumor

Mesh:

Substances:

Year:  2018        PMID: 29345008     DOI: 10.1111/iju.13519

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  7 in total

1.  Mixed germ cell tumor composed of a tridermic testicular teratoma and seminoma in a rooster.

Authors:  Vincent J Tavella; Jessica N Walters; Lisa M Crofton; Tanya LeRoith
Journal:  J Vet Diagn Invest       Date:  2019-03-12       Impact factor: 1.279

2.  Metastatic Testicular Seminoma in a Patient With Down Syndrome Presenting As Extensive Deep Venous Thrombosis.

Authors:  Meredith Hengy; Amita Hinge; James P Purtell; Kathren Shango; Joshua Collins
Journal:  Cureus       Date:  2022-09-11

3.  Pannexin1 inhibits autophagy of cisplatin-resistant testicular cancer cells by mediating ATP release.

Authors:  Min Yuan; Yanxue Yao; Dandan Wu; Chenlu Zhu; Shuying Dong; Xuhui Tong
Journal:  Cell Cycle       Date:  2022-04-03       Impact factor: 5.173

4.  Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors.

Authors:  Apostolia-Maria Tsimberidou; Henry Hiep Vo; Vivek Subbiah; Filip Janku; Sarina Piha-Paul; Bulent Yilmaz; Jing Gong; Mohammad Faraz Naqvi; Shi-Ming Tu; Matthew Campbell; Funda Meric-Bernstam; Aung Naing
Journal:  Oncologist       Date:  2021-02-12

5.  Ultrasound and Magnetic Resonance Imaging of Burned-Out Testicular Tumours: The Diagnostic Keys Based on 48 Cases.

Authors:  Thomas Desmousseaux; Emmanuel Arama; Florian Maxwell; Sophie Ferlicot; Chahinez Hani; Karim Fizazi; Cédric Lebacle; Yohann Loriot; Meriem Boumerzoug; Julian Cohen; Nada Garrouche; Laurence Rocher
Journal:  Cancers (Basel)       Date:  2022-08-19       Impact factor: 6.575

6.  Dataset of testicular germ cell tumors (TGCT) risk associated with serum polychlorinated biphenyl (PCB) by age at diagnosis and histologic types.

Authors:  Zhiyuan Cheng; Xichi Zhang; Bryan Bassig; Russ Hauser; Theodore R Holford; Elizabeth Zheng; Dian Shi; Yong Zhu; Stephen Marc Schwartz; Chu Chen; Kunchong Shi; Bo Yang; Zhengmin Qian; Peter Boyle; Tongzhang Zheng
Journal:  Data Brief       Date:  2021-03-27

7.  PDE11A gene polymorphism in testicular cancer: sperm parameters and hormonal profile.

Authors:  F Faja; F Finocchi; T Carlini; F Rizzo; F Pallotti; M Spaziani; G Balercia; A Lenzi; D Paoli; F Lombardo
Journal:  J Endocrinol Invest       Date:  2021-03-04       Impact factor: 4.256

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.